Cullinan Therapeutics, Inc.

Contributing Author

Recent Articles by Cullinan Therapeutics, Inc.

Jun-04	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases CGEM GlobeNewswire
May-29	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference CGEM GlobeNewswire
May-08	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results CGEM GlobeNewswire